Bloomlife

Bloomlife is a women's health company focused on developing remote maternal health solutions to improve the well-being of mothers and babies. The company combines connected devices with cloud-based analytics to enhance access to care, empower women, and provide clinicians with information to more effectively screen and manage pregnancy complications. Bloomlife's flagship product is the Bloomlife MFM-Pro, an FDA-cleared prescription-based wearable device designed to help healthcare providers measure maternal and fetal heart rates in patients' homes or clinics. The device non-invasively measures electrical activity of the body and uses cloud-based processing to algorithmically extract heart rate data. Bloomlife aims to shift care from high-cost clinical settings to the home, delivering evidence-based, cost-effective, high-quality, patient-centered care. The company's efforts are focused on addressing the global maternal health crisis by enabling earlier identification of complications and improving birth outcomes.

Key customers and partnerships

Bloomlife has established strategic partnerships to expand its reach and capabilities. In January 2024, the company partnered with PeriGen, a leader in applying artificial intelligence to improve safety in childbirth. This collaboration aims to combine Bloomlife's remote patient monitoring technology with PeriGen's data visualization and analytics to enhance monitoring of high-risk pregnancies. The partnership integrates Bloomlife's data into PeriGen's PeriWatch Vigilance software, leveraging advanced statistical tools to analyze patterns and alert clinicians to potential issues in real-time. In March 2024, Bloomlife also announced a commercial partnership with Valley Perinatal Services, Arizona's leading high-risk maternal fetal medicine group, to deploy its remote maternal care platform Bloomlife Connects. This platform focuses on hypertension management and has demonstrated improved adherence to blood pressure monitoring recommendations and better blood pressure control in initial studies.